{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:26:54Z","timestamp":1787725614519,"version":"build-2784847793"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI19\/0568"],"award-info":[{"award-number":["PI19\/0568"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III, Fondo Social Europeo","award":["FI20\/00211"],"award-info":[{"award-number":["FI20\/00211"]}]},{"name":"Gilead Sciences, S.L."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-53044-y","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:45:21Z","timestamp":1779259521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of community interventions to promote awareness, testing and treatment of hepatitis B and C in migrant populations in Catalonia"],"prefix":"10.1038","volume":"16","author":[{"given":"Elisa","family":"Martr\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Dom\u00ednguez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venus","family":"Forero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"G\u00f3mez i Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Not","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Manzanares-Laya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"G\u00f3mez-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Casabona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Maj\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Colom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"53044_CR1","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. https:\/\/www.who.int\/publications\/i\/item\/9789240091672."},{"key":"53044_CR2","unstructured":"European Centre for Disease Prevention and Control. Hepatitis B. Hepatitis B. In: ECDC. Annual epidemiological report for 2022. Stockholm: ECDC. (2024)."},{"key":"53044_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01885-0","volume":"11","author":"CA Picchio","year":"2021","unstructured":"Picchio, C. A. et al. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: A 2-year registry review. Sci. Rep. 11, 24133 (2021).","journal-title":"Sci. Rep."},{"key":"53044_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.gastrohep.2020.03.011","volume":"43","author":"M Rodr\u00edguez","year":"2020","unstructured":"Rodr\u00edguez, M. et al. Consensus document of the Spanish Association for Study of the Liver on the treatment of Hepatitis B virus infection (2020). Gastroenterol. Hepatol. 43, 559\u2013587 (2020).","journal-title":"Gastroenterol. Hepatol."},{"key":"53044_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.gastrohep.2018.07.010","volume":"41","author":"JL Calleja","year":"2018","unstructured":"Calleja, J. L. et al. Guidelines on treatment of hepatitis C virus infection. Spanish association for the study of the liver (AEEH). Gastroenterol. Hepatol. 41, 597\u2013608 (2018).","journal-title":"Gastroenterol. Hepatol."},{"key":"53044_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1118227","volume":"11","author":"CPB Moonen","year":"2023","unstructured":"Moonen, C. P. B. et al. A systematic review of barriers and facilitators for Hepatitis B and C screening among migrants in the EU\/EEA region. Front Public Health 11, 1118227 (2023).","journal-title":"Front Public Health"},{"key":"53044_CR7","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis. https:\/\/iris.who.int\/handle\/10665\/246177 (2016)."},{"key":"53044_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2908-5","volume":"18","author":"AM Falla","year":"2018","unstructured":"Falla, A. M., Ahmad, A. A., Duffell, E., Noori, T. & Veldhuijzen, I. K. Estimating the scale of chronic Hepatitis C virus infection in the EU\/EEA: A focus on migrants from anti-HCV endemic countries. BMC Infect. Dis. 18, 42 (2018).","journal-title":"BMC Infect. Dis."},{"key":"53044_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.eimc.2018.04.002","volume":"37","author":"JV Lazarus","year":"2019","unstructured":"Lazarus, J. V. et al. Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. Enferm. Infecc. Microbiol. Clin. (Engl Ed) 37, 222\u2013230 (2019).","journal-title":"Enferm. Infecc. Microbiol. Clin. (Engl Ed)"},{"key":"53044_CR10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1111\/jgh.14984","volume":"35","author":"S Rodr\u00edguez-Tajes","year":"2020","unstructured":"Rodr\u00edguez-Tajes, S. et al. Significant decrease in the prevalence of Hepatitis C infection after the introduction of direct acting antivirals. J. Gastroenterol. Hepatol. 35, 1570\u20131578 (2020).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"53044_CR11","unstructured":"Idescat. Idescat. Poblaci\u00f3n extranjera a 1 de enero. Por pa\u00edses. Catalu\u00f1a. https:\/\/www.idescat.cat\/poblacioestrangera\/?b=12&lang=es."},{"key":"53044_CR12","volume-title":"Epidemiological Assessment of Hepatitis B and C Among Migrants in the EU\/EEA","author":"European Centre for Disease Prevention and Control","year":"2016","unstructured":"European Centre for Disease Prevention and Control. Epidemiological Assessment of Hepatitis B and C Among Migrants in the EU\/EEA (ECDC, 2016)."},{"key":"53044_CR13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.17235\/reed.2019.6117\/2018","volume":"111","author":"ME Alarc\u00f3n Linares","year":"2019","unstructured":"Alarc\u00f3n Linares, M. E. et al. Geographic analysis and estimation of hepatitis C cases in migrant populations living in Spain: Is a country-based screening strategy appropriate?. Rev. Esp. Enferm. Dig. 111, 615\u2013625 (2019).","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"53044_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","volume":"7","author":"Polaris Observatory HCV Collaborators","year":"2022","unstructured":"Polaris Observatory HCV Collaborators. Global change in Hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study. Lancet Gastroenterol. Hepatol. 7, 396\u2013415 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"53044_CR15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","volume":"8","author":"Polaris Observatory Collaborators","year":"2023","unstructured":"Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of Hepatitis B in 2022: A modelling study. Lancet Gastroenterol. Hepatol. 8, 879\u2013907 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"53044_CR16","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/liv.15327","volume":"42","author":"E Martr\u00f3","year":"2022","unstructured":"Martr\u00f3, E. et al. Pilot hepatitis C micro-elimination strategy in Pakistani migrants in Catalonia through a community intervention. Liver Int 42, 1751\u20131761 (2022).","journal-title":"Liver Int"},{"key":"53044_CR17","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3390\/v15071506","volume":"15","author":"A Palom","year":"2023","unstructured":"Palom, A. et al. Community Strategy for Hepatitis B, C, and D Screening and Linkage to Care in Mongolians Living in Spain. Viruses 15, 1506 (2023).","journal-title":"Viruses"},{"key":"53044_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s43856-023-00420-8","volume":"3","author":"CA Picchio","year":"2023","unstructured":"Picchio, C. A. et al. Community-based screening enhances hepatitis B virus linkage to care among West African migrants in Spain. Commun. Med. (Lond) 3, 182 (2023).","journal-title":"Commun. Med. (Lond)"},{"key":"53044_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.aprim.2010.09.014","volume":"43","author":"LA Gimeno-Feliu","year":"2011","unstructured":"Gimeno-Feliu, L. A. et al. Frequency of attending primary care clinics by the immigrant versus autochthonous population. Aten. Primaria 43, 544\u2013550 (2011).","journal-title":"Aten. Primaria"},{"key":"53044_CR20","unstructured":"World Health Organization. Guidelines on hepatitis B and C testing. https:\/\/www.who.int\/publications\/i\/item\/9789241549981."},{"key":"53044_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2921-8","volume":"18","author":"AA Ahmad","year":"2018","unstructured":"Ahmad, A. A. et al. Estimating the scale of chronic hepatitis B virus infection among migrants in EU\/EEA countries. BMC Infect. Dis. 18, 34 (2018).","journal-title":"BMC Infect. Dis."},{"key":"53044_CR22","unstructured":"M\u00e9dicos del Mundo. III informe de Barreras al Sistema Nacional de Salud en poblaciones vulnerabilizadas. M\u00e9dicos del Mundo. https:\/\/www.medicosdelmundo.org\/actualidad\/publicaciones\/informes\/iii-informe-de-barreras-al-sistema-nacional-de-salud-en-poblaciones-vulnerabilizadas."},{"key":"53044_CR23","unstructured":"Joan, C., Xavier, M., & Xavier, Francesc. Outcomes of a community screening strategy for hepatitis B and C in migrant population from high prevalence countries in Catalonia (MiCatC). Paris. Fast-Track Cities (2024)."},{"key":"53044_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70126","volume":"45","author":"A Not","year":"2025","unstructured":"Not, A. et al. Hepatitis B and C screening and linkage to care in migrants from endemic countries in Barcelona through a community action. Liver Int. 45, e70126 (2025).","journal-title":"Liver Int."},{"key":"53044_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068460","volume":"13","author":"J Reyes-Urue\u00f1a","year":"2023","unstructured":"Reyes-Urue\u00f1a, J. et al. Implementation of the HepClink test-and-treat community strategy targeting Pakistani migrants with hepatitis C living in Catalonia (Spain) compared with the current practice of the Catalan health system: Budget impact analysis. BMJ Open 13, e068460 (2023).","journal-title":"BMJ Open"},{"key":"53044_CR26","unstructured":"Gencat. ORDRE SLT\/63\/2020, de 8 de mar\u00e7, per la qual s\u2019aproven els preus p\u00fablics del Servei Catal\u00e0 de la Salut. Portal Jur\u00eddic de Catalunya http:\/\/portaljuridic.gencat.cat\/ca\/document-del-pjur\/."},{"key":"53044_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260608","volume":"16","author":"A Garc\u00eda-Herola","year":"2021","unstructured":"Garc\u00eda-Herola, A., Dom\u00ednguez-Hern\u00e1ndez, R. & Casado, M. \u00c1. Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C. PLoS ONE 16, e0260608 (2021).","journal-title":"PLoS ONE"},{"key":"53044_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100932","volume":"6","author":"J Llaneras","year":"2024","unstructured":"Llaneras, J. et al. Integrating viral hepatitis management into the emergency department: A further step towards viral hepatitis elimination. JHEP Rep 6, 100932 (2024).","journal-title":"JHEP Rep"},{"key":"53044_CR29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.5604\/01.3001.0009.8590","volume":"16","author":"I Oyag\u00fcez","year":"2017","unstructured":"Oyag\u00fcez, I., Buti, M., Brosa, M., Rueda, M. & Casado, M. A. Cost-effectiveness and clinical impact of antiviral strategies of HBeAg-positive and -negative chronic hepatitis B. Ann. Hepatol. 16, 358\u2013365 (2017).","journal-title":"Ann. Hepatol."},{"key":"53044_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.gastrohep.2017.05.004","volume":"40","author":"J Turnes","year":"2017","unstructured":"Turnes, J., Dom\u00ednguez-Hern\u00e1ndez, R. & Casado, M. \u00c1. Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. Gastroenterol. Hepatol. 40, 433\u2013446 (2017).","journal-title":"Gastroenterol. Hepatol."},{"key":"53044_CR31","first-page":"809","volume":"109","author":"J Turnes","year":"2017","unstructured":"Turnes, J., Dom\u00ednguez-Hern\u00e1ndez, R. & Casado, M. \u00c1. Value and innovation of direct-acting antivirals: Long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. Rev. Esp. Enferm. Dig. 109, 809\u2013817 (2017).","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"53044_CR32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10198-010-0244-4","volume":"11","author":"J L\u00f3pez-Bastida","year":"2010","unstructured":"L\u00f3pez-Bastida, J. et al. Spanish recommendations on economic evaluation of health technologies. Eur. J. Health Econ. 11, 513\u2013520 (2010).","journal-title":"Eur. J. Health Econ."},{"key":"53044_CR33","unstructured":"Instituto Nacional de Estad\u00edstica (INE). C\u00e1lculo de variaciones del Indice de Precios de Consumo. INE https:\/\/www.ine.es\/varipc\/index.do;jsessionid=4CCA9CB21B91C0EE11EBCF4B574F9C5C.varipc03."},{"key":"53044_CR34","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43, 1317\u20131325 (2006).","journal-title":"Hepatology"},{"key":"53044_CR35","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/S2214-109X(21)00517-9","volume":"10","author":"S Su","year":"2022","unstructured":"Su, S. et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: An economic evaluation. Lancet Glob Health. 10, e278\u2013e287 (2022).","journal-title":"Lancet Glob Health."},{"key":"53044_CR36","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","volume":"71","author":"J Llaneras","year":"2019","unstructured":"Llaneras, J. et al. Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J. Hepatol. 71, 666\u2013672 (2019).","journal-title":"J. Hepatol."},{"issue":"2","key":"53044_CR37","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL 2025 clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol. 83(2), 502\u2013583 (2025).","journal-title":"J. Hepatol."},{"key":"53044_CR38","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/liv.15814","volume":"44","author":"A Feliu-Prius","year":"2024","unstructured":"Feliu-Prius, A. et al. Assessing the rate of non-linkage to care and identifying barriers in individuals living with hepatitis B. Results of the LINK-B study. Liver Int. 44, 706\u2013714 (2024).","journal-title":"Liver Int."},{"key":"53044_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01837-y","volume":"21","author":"Y-T Huang","year":"2021","unstructured":"Huang, Y.-T. et al. Sofosbuvir\/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. BMC Gastroenterol. 21, 259 (2021).","journal-title":"BMC Gastroenterol."},{"key":"53044_CR40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/gastro\/goaa010","volume":"8","author":"M Miquel","year":"2020","unstructured":"Miquel, M. et al. Current trends in access to treatment for hepatitis B in immigrants vs. non-immigrants. Gastroenterol Rep (Oxf) 8, 362\u2013366 (2020).","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"53044_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40273-024-01441-4","volume":"43","author":"L Vallejo-Torres","year":"2025","unstructured":"Vallejo-Torres, L. Estimating the incremental cost per QALY produced by the Spanish NHS: A fixed-effect econometric approach. Pharmacoeconomics 43, 109\u2013122 (2025).","journal-title":"Pharmacoeconomics"},{"key":"53044_CR42","unstructured":"Ministerio de Sanidad. 2\u00b0 Estudio de Seroprevalencia en Espa\u00f1a. Available at: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/comoTrabajamos\/EstudioSeroprevalencia.htm."},{"key":"53044_CR43","unstructured":"Gu\u00eda de Cribado de infecci\u00f3n por el VHC. Divisi\u00f3n de Control del VIH, ITS, Hepatitis Virales y Tuberculosis. Ministerio de Sanidad (2022). https:\/\/www.sanidad.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/hepatitis\/GUIIA_DE_CRIBADO_DE_LA_INFECCION_POR_EL_VHC_2020_rev21-10-2022.pdf."},{"key":"53044_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmh.2024.100278","volume":"10","author":"A Cruz","year":"2024","unstructured":"Cruz, A. et al. Estimating the prevalence of chronic infections among asymptomatic migrants: Results of a screening programme in Catalonia, Spain. J. Migr. Health 10, 100278 (2024).","journal-title":"J. Migr. Health"},{"key":"53044_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15092013","volume":"15","author":"C Greenaway","year":"2018","unstructured":"Greenaway, C. et al. The effectiveness and cost-effectiveness of hepatitis C screening for migrants in the EU\/EEA: A systematic review. Int. J. Environ. Res. Public Health 15, 2013 (2018).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"53044_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208036","volume":"13","author":"M Buti","year":"2018","unstructured":"Buti, M., Dom\u00ednguez-Hern\u00e1ndez, R., Casado, M. \u00c1., Sabater, E. & Esteban, R. Healthcare value of implementing hepatitis C screening in the adult general population in Spain. PLoS ONE 13, e0208036 (2018).","journal-title":"PLoS ONE"},{"key":"53044_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s41669-023-00458-3","volume":"8","author":"JL Calleja","year":"2024","unstructured":"Calleja, J. L. et al. The efficiency of increased HCV testing and treatment strategies in Spain to achieve elimination goals. Pharmacoecon. Open 8, 221\u2013233 (2024).","journal-title":"Pharmacoecon. Open"},{"key":"53044_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207037","volume":"13","author":"AWM Suijkerbuijk","year":"2018","unstructured":"Suijkerbuijk, A. W. M. et al. Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country. PLoS ONE 13, e0207037 (2018).","journal-title":"PLoS ONE"},{"key":"53044_CR49","doi-asserted-by":"publisher","unstructured":"Public Health Guidance on HIV, Hepatitis B and C Testing in the EU\/EEA: An Integrated Approach. (ECDC, Stockholm, 2018). https:\/\/doi.org\/10.2900\/79127. Available at: www.ecdc.europa.eu\/sites\/default\/files\/documents\/hiv-hep-testing-guidance_0.pdf.","DOI":"10.2900\/79127"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53044-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53044-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53044-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:41:13Z","timestamp":1784677273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53044-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53044"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53044-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EM has received lecture fees and research grants from Abbott GmbH & Co.K.G., Gilead Sciences, Cepheid and Abbvie, outside of the submitted work. RDH and MGB are employees of Pharmacoeconomics & Outcomes Research Iberia (PORIB), a consulting firm specializing in the economic evaluation of health care interventions that has received financing for the development of the project that is not conditional upon the results. MB: has received lecture fees and research grants from Abbvie, GSK and Gilead Sciences, outside of the submitted work. VF, JG, AN, SML, MM, JC, XM and JC declare no competing interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22904"}}